BIOLIFE SOLUTIONS INC (BLFS) Stock Fundamental Analysis

NASDAQ:BLFS • US09062W2044

23.23 USD
+0.39 (+1.71%)
At close: Feb 19, 2026
23.23 USD
0 (0%)
After Hours: 2/19/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Overall BLFS gets a fundamental rating of 5 out of 10. We evaluated BLFS against 58 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for BLFS as it has an excellent financial health rating, but there are worries on the profitability. BLFS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year BLFS was profitable.
  • In the past year BLFS had a positive cash flow from operations.
  • BLFS had negative earnings in 4 of the past 5 years.
  • In multiple years BLFS reported negative operating cash flow during the last 5 years.
BLFS Yearly Net Income VS EBIT VS OCF VS FCFBLFS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • BLFS's Return On Assets of -0.82% is fine compared to the rest of the industry. BLFS outperforms 62.07% of its industry peers.
  • BLFS's Return On Equity of -0.91% is fine compared to the rest of the industry. BLFS outperforms 67.24% of its industry peers.
Industry RankSector Rank
ROA -0.82%
ROE -0.91%
ROIC N/A
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
BLFS Yearly ROA, ROE, ROICBLFS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

  • BLFS has a better Gross Margin (70.02%) than 93.10% of its industry peers.
  • In the last couple of years the Gross Margin of BLFS has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for BLFS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
BLFS Yearly Profit, Operating, Gross MarginsBLFS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BLFS has been increased compared to 1 year ago.
  • The number of shares outstanding for BLFS has been increased compared to 5 years ago.
  • BLFS has a better debt/assets ratio than last year.
BLFS Yearly Shares OutstandingBLFS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BLFS Yearly Total Debt VS Total AssetsBLFS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • BLFS has an Altman-Z score of 16.48. This indicates that BLFS is financially healthy and has little risk of bankruptcy at the moment.
  • BLFS's Altman-Z score of 16.48 is amongst the best of the industry. BLFS outperforms 100.00% of its industry peers.
  • BLFS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.48
ROIC/WACCN/A
WACC10.89%
BLFS Yearly LT Debt VS Equity VS FCFBLFS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • BLFS has a Current Ratio of 4.66. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
  • BLFS has a better Current ratio (4.66) than 74.14% of its industry peers.
  • A Quick Ratio of 3.64 indicates that BLFS has no problem at all paying its short term obligations.
  • The Quick ratio of BLFS (3.64) is better than 65.52% of its industry peers.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 3.64
BLFS Yearly Current Assets VS Current LiabilitesBLFS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • BLFS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 123.36%, which is quite impressive.
  • The Revenue for BLFS has decreased by -24.98% in the past year. This is quite bad
  • BLFS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.59% yearly.
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%

3.2 Future

  • BLFS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.91% yearly.
  • The Revenue is expected to grow by 15.63% on average over the next years. This is quite good.
EPS Next Y32.33%
EPS Next 2Y47.65%
EPS Next 3Y40.1%
EPS Next 5Y29.91%
Revenue Next Year-10.81%
Revenue Next 2Y1.83%
Revenue Next 3Y8.04%
Revenue Next 5Y15.63%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BLFS Yearly Revenue VS EstimatesBLFS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
BLFS Yearly EPS VS EstimatesBLFS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 92.92, BLFS can be considered very expensive at the moment.
  • The rest of the industry has a similar Price/Earnings ratio as BLFS.
  • The average S&P500 Price/Earnings ratio is at 27.09. BLFS is valued rather expensively when compared to this.
  • A Price/Forward Earnings ratio of 253.05 indicates a quite expensive valuation of BLFS.
  • BLFS's Price/Forward Earnings ratio is in line with the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.98, BLFS is valued quite expensively.
Industry RankSector Rank
PE 92.92
Fwd PE 253.05
BLFS Price Earnings VS Forward Price EarningsBLFS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200 250

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as BLFS.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 205.55
BLFS Per share dataBLFS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLFS does not grow enough to justify the current Price/Earnings ratio.
  • BLFS's earnings are expected to grow with 40.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.87
PEG (5Y)N/A
EPS Next 2Y47.65%
EPS Next 3Y40.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BLFS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOLIFE SOLUTIONS INC

NASDAQ:BLFS (2/19/2026, 8:00:01 PM)

After market: 23.23 0 (0%)

23.23

+0.39 (+1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners103.55%
Inst Owner Change0.71%
Ins Owners2%
Ins Owner Change-1.39%
Market Cap1.12B
Revenue(TTM)88.83M
Net Income(TTM)-3.21M
Analysts83.75
Price Target32.87 (41.5%)
Short Float %6.19%
Short Ratio8.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)128.28%
Min EPS beat(2)72.55%
Max EPS beat(2)184.01%
EPS beat(4)4
Avg EPS beat(4)208.62%
Min EPS beat(4)72.55%
Max EPS beat(4)496.49%
EPS beat(8)7
Avg EPS beat(8)84.53%
EPS beat(12)8
Avg EPS beat(12)5.02%
EPS beat(16)10
Avg EPS beat(16)1.09%
Revenue beat(2)2
Avg Revenue beat(2)6.11%
Min Revenue beat(2)5.11%
Max Revenue beat(2)7.1%
Revenue beat(4)4
Avg Revenue beat(4)5.3%
Min Revenue beat(4)3.34%
Max Revenue beat(4)7.1%
Revenue beat(8)7
Avg Revenue beat(8)8.78%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.21%
PT rev (1m)0.38%
PT rev (3m)2.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-160.14%
EPS NY rev (1m)0%
EPS NY rev (3m)6.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.73%
Valuation
Industry RankSector Rank
PE 92.92
Fwd PE 253.05
P/S 12.59
P/FCF N/A
P/OCF 66.41
P/B 3.16
P/tB 8.35
EV/EBITDA 205.55
EPS(TTM)0.25
EY1.08%
EPS(NY)0.09
Fwd EY0.4%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.35
OCFY1.51%
SpS1.84
BVpS7.35
TBVpS2.78
PEG (NY)2.87
PEG (5Y)N/A
Graham Number6.43
Profitability
Industry RankSector Rank
ROA -0.82%
ROE -0.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.02%
FCFM N/A
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
F-Score6
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 298.5%
Cap/Sales 19.51%
Interest Coverage N/A
Cash Conversion 353.72%
Profit Quality N/A
Current Ratio 4.66
Quick Ratio 3.64
Altman-Z 16.48
F-Score6
WACC10.89%
ROIC/WACCN/A
Cap/Depr(3y)80.15%
Cap/Depr(5y)101.86%
Cap/Sales(3y)10.07%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
EPS Next Y32.33%
EPS Next 2Y47.65%
EPS Next 3Y40.1%
EPS Next 5Y29.91%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%
Revenue Next Year-10.81%
Revenue Next 2Y1.83%
Revenue Next 3Y8.04%
Revenue Next 5Y15.63%
EBIT growth 1Y95.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year321.45%
EBIT Next 3Y86.13%
EBIT Next 5YN/A
FCF growth 1Y97.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y342.36%
OCF growth 3YN/A
OCF growth 5Y47.44%

BIOLIFE SOLUTIONS INC / BLFS FAQ

What is the ChartMill fundamental rating of BIOLIFE SOLUTIONS INC (BLFS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to BLFS.


Can you provide the valuation status for BIOLIFE SOLUTIONS INC?

ChartMill assigns a valuation rating of 2 / 10 to BIOLIFE SOLUTIONS INC (BLFS). This can be considered as Overvalued.


Can you provide the profitability details for BIOLIFE SOLUTIONS INC?

BIOLIFE SOLUTIONS INC (BLFS) has a profitability rating of 3 / 10.


Can you provide the PE and PB ratios for BLFS stock?

The Price/Earnings (PE) ratio for BIOLIFE SOLUTIONS INC (BLFS) is 92.92 and the Price/Book (PB) ratio is 3.16.


What is the expected EPS growth for BIOLIFE SOLUTIONS INC (BLFS) stock?

The Earnings per Share (EPS) of BIOLIFE SOLUTIONS INC (BLFS) is expected to grow by 32.33% in the next year.